サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1492298

転移性黒色腫がん診断市場：世界の産業分析、規模、シェア、成長、動向、予測、2024～2033年

Metastatic Melanoma Cancer Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日
ページ情報
英文 201 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
転移性黒色腫がん診断市場：世界の産業分析、規模、シェア、成長、動向、予測、2024～2033年
出版日: 2024年05月27日
発行: Persistence Market Research
ページ情報: 英文 201 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Researchはこのほど、転移性黒色腫がん診断市場の詳細な分析を実施し、その世界情勢を幅広く掘り下げた包括的な報告書をまとめました。この詳細な出版物は、市場力学、動向、機会、課題に関する貴重な洞察を提供し、その構造の完全な概観を提供します。独占データと統計の裏付けにより、調査は2024年から2033年までの転移性黒色腫がん診断市場の予測成長軌道を予測します。

世界の転移性黒色腫がん診断市場は、2024年に37億米ドルの収益を生み出すと予測されます。CAGR7.8％で成長すると予測され、2033年末までには72億米ドルの評価額に達すると予測されます。

主要な洞察

  • 転移性黒色腫がん診断市場規模（2024年）：37億米ドル
  • 予測市場金額（2033年）：72億米ドル
  • 世界市場成長率（CAGR、2024～2033年）：7.8%

転移性黒色腫がん診断市場 - レポート範囲：

転移性黒色腫がん診断は、深刻な皮膚がんである黒色腫の早期発見と治療に重要な役割を果たしています。診断ツールや診断方法には、画像検査、生検、分子検査、血液検査などがあり、黒色腫の体の他の部位への広がりを特定するのに役立ちます。この市場は、病院、診療所、診断研究所、研究機関を対象としており、さまざまな診断技術やサービスを提供しています。市場成長の促進力は、黒色腫の罹患率の増加、診断技術の進歩、早期発見と個別化医療の重視の高まりです。

市場成長の促進要因：

世界の転移性黒色腫がん診断市場は、効率的で早期診断ソリューションが必要とされる黒色腫罹患率の上昇など、いくつかの重要な要因によって推進されています。次世代シーケンシング（NGS）やリキッドバイオプシーなどの診断ツールの技術的進歩は、黒色腫検出の精度とスピードを高め、市場拡大に寄与しています。個別化医療や標的療法の採用が増加していることも、黒色腫に関する詳細な遺伝子・分子情報を提供できる高度な診断方法に対する需要をさらに押し上げています。さらに、皮膚がんに対する意識の高まりと検診プログラムが早期診断を促し、治療成績の向上と市場成長の原動力となっています。

市場抑制要因：

有望な成長が見込まれるものの、転移性黒色腫の診断市場は、地域によっては高コストや高度な診断ツールの入手制限に関連する課題に直面しています。特にヘルスケア予算に制約のある新興国では、診断手順や機器の高額なコストが普及の障壁となる可能性があります。また、新しい診断技術に対する規制上のハードルや厳しい承認プロセスも、市場参入や商業化を遅らせる要因となっています。さらに、地域によって診断検査に対する償還政策にばらつきがあることも市場成長に影響し、メーカーやヘルスケアプロバイダーは複雑な規制状況を乗り切る必要があります。

市場機会：

転移性黒色腫がん診断市場は、診断技術の革新、ヘルスケアインフラの拡大、がん研究への投資の増加により、大きな成長機会をもたらしています。診断ツールに人工知能（AI）と機械学習（ML）を統合することで、精度と効率が向上し、早期発見と個別化治療計画に新たな可能性がもたらされます。リキッドバイオプシーなどの非侵襲的・低侵襲的診断法の開拓は、患者により安全で便利な選択肢を提供し、市場範囲を拡大します。戦略的パートナーシップ、調査協力、新興市場への投資は、こうした機会を活用し、市場のリーダーシップを維持するために不可欠です。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲 / 分類
  • 市場の定義 / 範囲 / 制限
  • 包含事項・除外事項

第3章 主要な市場動向

  • 市場に影響を与える主要な動向
  • イノベーション / 開発動向

第4章 主要な成功要因

  • 疾病疫学：地域別
  • 規制状況
  • 検査採用率
  • 技術の進歩
  • 払い戻しシナリオ
  • PESTEL分析
  • ポーターの分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因 - 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 検査別
    • サービスプロバイダー別
    • 国別
  • 2024年の市場シナリオ

第7章 世界の転移性黒色腫がん診断市場の需要分析

  • 過去の市場金額分析、2019～2023年
  • 現在および将来の市場金額予測、2024～2033年
    • 前年比成長動向分析
    • 絶対額の機会分析

第8章 世界の転移性黒色腫がん診断市場分析：検査別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模分析：検査別、2019～2023年
  • 現在および将来の市場規模の分析と予測：検査別、2024～2033年
    • 生検
    • 胸部X線
    • 超音波
    • CTスキャン
    • MRI
    • PETスキャン
  • 市場魅力度分析：検査別

第9章 世界の転移性黒色腫がん診断市場分析：サービスプロバイダー別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模分析：サービスプロバイダー別、2019～2023年
  • 現在および将来の市場規模分析と予測：サービスプロバイダー別、2024～2033年
    • 病院
    • 病理学研究室
    • がん研究センター
  • 市場魅力度分析：サービスプロバイダー別

第10章 世界の転移性黒色腫がん診断市場分析：地域別

  • イントロダクション
  • 過去の市場規模分析：地域別、2019～2023年
  • 現在および将来の市場金額の分析と予測：地域別、2024～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ（MEA）
  • 市場魅力度分析：地域別

第11章 北米の転移性黒色腫がん診断市場分析

第12章 ラテンアメリカの転移性黒色腫がん診断市場分析

第13章 欧州の転移性黒色腫がん診断市場分析

第14章 東アジアの転移性黒色腫がん診断市場分析

第15章 南アジアの転移性黒色腫がん診断市場分析

第16章 オセアニアの転移性黒色腫がん診断市場

第17章 中東・アフリカ（MEA）の転移性黒色腫がん診断市場分析

第18章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細
    • Amgen Inc
    • Abbott Laboratories
    • Bristol-Myers Squibb
    • Novartis AG
    • F-Hoffmann-La Roche Ltd
    • Biomerieux
    • Quest diagnostics
    • Agilent Technologies Inc
    • Myriad Genetics Inc
    • Qiagen

第19章 使用される前提条件と頭字語

第20章 調査手法

目次
Product Code: PMRREP32446

Persistence Market Research recently conducted an in-depth analysis of the Metastatic Melanoma Cancer Diagnostics Market, resulting in a comprehensive report that delves extensively into its global landscape. This detailed publication provides valuable insights into the market's dynamics, trends, opportunities, and challenges, offering a thorough overview of its structure. With the support of exclusive data and statistics, the research predicts the anticipated growth trajectory of the Metastatic Melanoma Cancer Diagnostics Market spanning from 2024 to 2033.

The global metastatic melanoma cancer diagnostics market is expected to generate revenue of USD 3.7 billion in 2024. Projected to grow at a compound annual growth rate (CAGR) of 7.8%, the market is anticipated to reach a valuation of USD 7.2 billion by the end of 2033.

Key Insights:

  • Metastatic Melanoma Cancer Diagnostics Market Size (2024): USD 3.7 billion
  • Projected Market Value (2033):USD 7.2 billion
  • Global Market Growth Rate (CAGR 2024-2033):7.8%

Metastatic Melanoma Cancer Diagnostics Market - Report Scope:

Metastatic melanoma cancer diagnostics play a crucial role in the early detection and treatment of melanoma, a serious form of skin cancer. Diagnostics tools and methods include imaging tests, biopsies, molecular tests, and blood tests that help in identifying the spread of melanoma to other parts of the body. The market caters to hospitals, clinics, diagnostic laboratories, and research institutes, offering a range of diagnostic technologies and services. Market growth is driven by increasing incidence rates of melanoma, advancements in diagnostic technologies, and a growing emphasis on early detection and personalized medicine.

Market Growth Drivers:

The global metastatic melanoma cancer diagnostics market is propelled by several key factors, including rising melanoma incidence rates, which necessitate efficient and early diagnostic solutions. Technological advancements in diagnostic tools, such as next-generation sequencing (NGS) and liquid biopsy, enhance the accuracy and speed of melanoma detection, contributing to market expansion. The increasing adoption of personalized medicine and targeted therapies further drives demand for advanced diagnostic methods that can provide detailed genetic and molecular information about melanoma. Additionally, heightened awareness and screening programs for skin cancer encourage early diagnosis, improving treatment outcomes and fueling market growth.

Market Restraints:

Despite promising growth prospects, the metastatic melanoma cancer diagnostics market faces challenges related to high costs and limited accessibility of advanced diagnostic tools in some regions. The high cost of diagnostic procedures and equipment can be a barrier to widespread adoption, particularly in emerging economies with constrained healthcare budgets. Regulatory hurdles and stringent approval processes for new diagnostic technologies can also delay market entry and commercialization. Furthermore, variability in reimbursement policies for diagnostic tests across different regions impacts market growth, requiring manufacturers and healthcare providers to navigate complex regulatory landscapes.

Market Opportunities:

The metastatic melanoma cancer diagnostics market presents significant growth opportunities driven by innovations in diagnostic technologies, expanding healthcare infrastructure, and increasing investment in cancer research. The integration of artificial intelligence (AI) and machine learning (ML) in diagnostic tools enhances accuracy and efficiency, offering new possibilities for early detection and personalized treatment plans. The development of non-invasive and minimally invasive diagnostic methods, such as liquid biopsy, provides safer and more convenient options for patients, broadening the market scope. Strategic partnerships, research collaborations, and investment in emerging markets are essential to capitalize on these opportunities and sustain market leadership.

Competitive Intelligence and Business Strategy:

Leading players in the global metastatic melanoma cancer diagnostics market, including F. Hoffmann-La Roche Ltd., Illumina, Inc., and Agilent Technologies, Inc., focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced diagnostic solutions, including NGS, liquid biopsy, and molecular diagnostics, catering to diverse patient needs and clinical requirements. Collaborations with healthcare providers, research institutes, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the rapidly evolving melanoma diagnostics landscape.

Key Companies Profiled:

  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories, Inc.
  • Bio-Rad Laboratories, Inc.
  • Guardant Health, Inc.
  • Castle Biosciences, Inc.

Key Segments Covered in Metastatic Melanoma Cancer Diagnostics Industry Research

Test:

  • Biopsy
  • Chest X-ray
  • Ultrasound
  • CT Scan
  • MRI
  • PET SCAN

Service Provider:

  • Hospitals
  • Pathology Laboratories
  • Cancer Research Centres

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Innovation / Development Trends

4. Key Success Factors

  • 4.1. Disease Epidemiology, by Region
  • 4.2. Regulatory Landscape
  • 4.3. Test Adoption Rates
  • 4.4. Technological Advancements
  • 4.5. Reimbursement Scenario
  • 4.6. PESTEL Analysis
  • 4.7. Porter's Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Global Cancer Diagnostics Market Overview
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Test Adoption Rates
    • 5.2.2. Frequency of New Test Launches
    • 5.2.3. Regulatory Scenario
    • 5.2.4. Increasing Number of Cancer Prevention Techniques
    • 5.2.5. Epidemiology of Skin Cancer
    • 5.2.6. Reimbursement Scenario
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Test
    • 6.1.2. By Service Provider
    • 6.1.3. By Country
  • 6.2. 2024 Market Scenario

7. Global Metastatic Melanoma Cancer Diagnostics Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033, By Test

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis By Test, 2019-2023
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Test, 2024-2033
    • 8.3.1. Biopsy
      • 8.3.1.1. Local excision/excisional biopsy
      • 8.3.1.2. Punch biopsy
      • 8.3.1.3. Shave biopsy
      • 8.3.1.4. Fine needle aspiration (FNA) biopsy
      • 8.3.1.5. Sentinel lymph node biopsy
    • 8.3.2. Chest X-ray
    • 8.3.3. Ultrasound
    • 8.3.4. CT Scan
    • 8.3.5. MRI
    • 8.3.6. PET SCAN
  • 8.4. Market Attractiveness Analysis By Test

9. Global Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033, By Service Provider

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Service Provider, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Service Provider, 2024-2033
    • 9.3.1. Hospitals
    • 9.3.2. Pathology Laboratories
    • 9.3.3. Cancer Research Centers
  • 9.4. Market Attractiveness Analysis By Service Provider

10. Global Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
  • 10.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Region, 2024-2033
    • 10.3.1. North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. East Asia
    • 10.3.5. South Asia
    • 10.3.6. Oceania
    • 10.3.7. Middle East and Africa (MEA)
  • 10.4. Market Attractiveness Analysis By Region

11. North America Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
  • 11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 11.3.1. By Country
      • 11.3.1.1. U.S.
      • 11.3.1.2. Canada
    • 11.3.2. By Test
    • 11.3.3. By Service Provider
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Country
    • 11.4.2. By Test
    • 11.4.3. By Service Provider
  • 11.5. Market Trends
  • 11.6. Drivers and Restraints - Impact Analysis
  • 11.7. Country Level Analysis & Forecast
    • 11.7.1. U.S. Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 11.7.1.1. Introduction
      • 11.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 11.7.1.2.1. By Test
        • 11.7.1.2.2. By Service Provider
    • 11.7.2. Canada Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 11.7.2.1. Introduction
      • 11.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 11.7.2.2.1. By Test
        • 11.7.2.2.2. By Service Provider

12. Latin America Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 12.3.1. By Country
      • 12.3.1.1. Mexico
      • 12.3.1.2. Brazil
      • 12.3.1.3. Argentina
      • 12.3.1.4. Rest of Latin America
    • 12.3.2. By Test
    • 12.3.3. By Service Provider
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Test
    • 12.4.3. By Service Provider
  • 12.5. Market Trends
  • 12.6. Drivers and Restraints - Impact Analysis
  • 12.7. Country Level Analysis & Forecast
    • 12.7.1. Mexico Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 12.7.1.1. Introduction
      • 12.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.7.1.2.1. By Test
        • 12.7.1.2.2. By Service Provider
    • 12.7.2. Brazil Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 12.7.2.1. Introduction
      • 12.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.7.2.2.1. By Test
        • 12.7.2.2.2. By Service Provider
    • 12.7.3. Argentina Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 12.7.3.1. Introduction
      • 12.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 12.7.3.2.1. By Test
        • 12.7.3.2.2. By Service Provider

13. Europe Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. Germany
      • 13.3.1.2. Italy
      • 13.3.1.3. France
      • 13.3.1.4. U.K.
      • 13.3.1.5. Spain
      • 13.3.1.6. BENELUX
      • 13.3.1.7. Russia
      • 13.3.1.8. Rest of Europe
    • 13.3.2. By Test
    • 13.3.3. By Service Provider
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Test
    • 13.4.3. By Service Provider
  • 13.5. Market Trends
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Country Level Analysis & Forecast
    • 13.7.1. Germany Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 13.7.1.1. Introduction
      • 13.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.7.1.2.1. By Test
        • 13.7.1.2.2. By Service Provider
    • 13.7.2. Italy Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 13.7.2.1. Introduction
      • 13.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.7.2.2.1. By Test
        • 13.7.2.2.2. By Service Provider
    • 13.7.3. France Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 13.7.3.1. Introduction
      • 13.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.7.3.2.1. By Test
        • 13.7.3.2.2. By Service Provider
    • 13.7.4. U.K. Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 13.7.4.1. Introduction
      • 13.7.4.2. Market Analysis and Forecast by Market Taxonomy
        • 13.7.4.2.1. By Test
        • 13.7.4.2.2. By Service Provider
    • 13.7.5. Spain Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 13.7.5.1. Introduction
      • 13.7.5.2. Market Analysis and Forecast by Market Taxonomy
        • 13.7.5.2.1. By Test
        • 13.7.5.2.2. By Service Provider
    • 13.7.6. BENELUX Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 13.7.6.1. Introduction
      • 13.7.6.2. Market Analysis and Forecast by Market Taxonomy
        • 13.7.6.2.1. By Test
        • 13.7.6.2.2. By Service Provider
    • 13.7.7. Russia Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 13.7.7.1. Introduction
      • 13.7.7.2. Market Analysis and Forecast by Market Taxonomy
        • 13.7.7.2.1. By Test
        • 13.7.7.2.2. By Service Provider

14. East Asia Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. China
      • 14.3.1.2. Japan
      • 14.3.1.3. South Korea
    • 14.3.2. By Test
    • 14.3.3. By Service Provider
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Test
    • 14.4.3. By Service Provider
  • 14.5. Market Trends
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Country Level Analysis & Forecast
    • 14.7.1. China Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 14.7.1.1. Introduction
      • 14.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.7.1.2.1. By Test
        • 14.7.1.2.2. By Service Provider
    • 14.7.2. Japan Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 14.7.2.1. Introduction
      • 14.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.7.2.2.1. By Test
        • 14.7.2.2.2. By Service Provider
    • 14.7.3. South Korea Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 14.7.3.1. Introduction
      • 14.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.7.3.2.1. By Test
        • 14.7.3.2.2. By Service Provider

15. South Asia Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Indonesia
      • 15.3.1.3. Malaysia
      • 15.3.1.4. Thailand
      • 15.3.1.5. Rest of South Asia
    • 15.3.2. By Test
    • 15.3.3. By Service Provider
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Test
    • 15.4.3. By Service Provider
  • 15.5. Market Trends
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Country Level Analysis & Forecast
    • 15.7.1. India Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 15.7.1.1. Introduction
      • 15.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.1.2.1. By Test
        • 15.7.1.2.2. By Service Provider
    • 15.7.2. Indonesia Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 15.7.2.1. Introduction
      • 15.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.2.2.1. By Test
        • 15.7.2.2.2. By Service Provider
    • 15.7.3. Malaysia Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 15.7.3.1. Introduction
      • 15.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.3.2.1. By Test
        • 15.7.3.2.2. By Service Provider
    • 15.7.4. Thailand Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 15.7.4.1. Introduction
      • 15.7.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.7.4.2.1. By Test
        • 15.7.4.2.2. By Service Provider

16. Oceania Metastatic Melanoma Cancer Diagnostics Market 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. Australia
      • 16.3.1.2. New Zealand
    • 16.3.2. By Test
    • 16.3.3. By Service Provider
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Test
    • 16.4.3. By Service Provider
  • 16.5. Key Market Participants - Intensity Mapping
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Country Level Analysis & Forecast
    • 16.7.1. Australia Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 16.7.1.1. Introduction
      • 16.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.7.1.2.1. By Test
        • 16.7.1.2.2. By Service Provider
    • 16.7.2. New Zealand Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 16.7.2.1. Introduction
      • 16.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.7.2.2.1. By Test
        • 16.7.2.2.2. By Service Provider

17. Middle East and Africa (MEA) Metastatic Melanoma Cancer Diagnostics Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) Trend and Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. GCC Countries
      • 17.3.1.2. Turkey
      • 17.3.1.3. North Africa
      • 17.3.1.4. South Africa
      • 17.3.1.5. Rest of Middle East and Africa
    • 17.3.2. By Test
    • 17.3.3. By Service Provider
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Test
    • 17.4.3. By Service Provider
  • 17.5. Market Trends
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Country Level Analysis & Forecast
    • 17.7.1. GCC Countries Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 17.7.1.1. Introduction
      • 17.7.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.7.1.2.1. By Test
        • 17.7.1.2.2. By Service Provider
    • 17.7.2. Turkey Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 17.7.2.1. Introduction
      • 17.7.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.7.2.2.1. By Test
        • 17.7.2.2.2. By Service Provider
    • 17.7.3. South Africa Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 17.7.3.1. Introduction
      • 17.7.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.7.3.2.1. By Test
        • 17.7.3.2.2. By Service Provider
    • 17.7.4. North Africa Metastatic Melanoma Cancer Diagnostics Market Analysis
      • 17.7.4.1. Introduction
      • 17.7.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.7.4.2.1. By Test
        • 17.7.4.2.2. By Service Provider

18. Competition Analysis

  • 18.1. Competition Dashboard
  • 18.2. Competition Benchmarking
  • 18.3. Competition Deep Dive
    • 18.3.1. Amgen Inc
      • 18.3.1.1. Overview
      • 18.3.1.2. Product Portfolio
      • 18.3.1.3. Sales Footprint
      • 18.3.1.4. Strategy Overview
    • 18.3.2. Abbott Laboratories
      • 18.3.2.1. Overview
      • 18.3.2.2. Product Portfolio
      • 18.3.2.3. Sales Footprint
      • 18.3.2.4. Strategy Overview
    • 18.3.3. Bristol-Myers Squibb
      • 18.3.3.1. Overview
      • 18.3.3.2. Product Portfolio
      • 18.3.3.3. Sales Footprint
      • 18.3.3.4. Strategy Overview
    • 18.3.4. Novartis AG
      • 18.3.4.1. Overview
      • 18.3.4.2. Product Portfolio
      • 18.3.4.3. Sales Footprint
      • 18.3.4.4. Strategy Overview
    • 18.3.5. F-Hoffmann-La Roche Ltd
      • 18.3.5.1. Overview
      • 18.3.5.2. Product Portfolio
      • 18.3.5.3. Sales Footprint
      • 18.3.5.4. Strategy Overview
    • 18.3.6. Biomerieux
      • 18.3.6.1. Overview
      • 18.3.6.2. Product Portfolio
      • 18.3.6.3. Sales Footprint
      • 18.3.6.4. Strategy Overview
    • 18.3.7. Quest diagnostics
      • 18.3.7.1. Overview
      • 18.3.7.2. Product Portfolio
      • 18.3.7.3. Sales Footprint
      • 18.3.7.4. Strategy Overview
    • 18.3.8. Agilent Technologies Inc
      • 18.3.8.1. Overview
      • 18.3.8.2. Product Portfolio
      • 18.3.8.3. Sales Footprint
      • 18.3.8.4. Strategy Overview
    • 18.3.9. Myriad Genetics Inc
      • 18.3.9.1. Overview
      • 18.3.9.2. Product Portfolio
      • 18.3.9.3. Sales Footprint
      • 18.3.9.4. Strategy Overview
    • 18.3.10. Qiagen
      • 18.3.10.1. Overview
      • 18.3.10.2. Product Portfolio
      • 18.3.10.3. Sales Footprint
      • 18.3.10.4. Strategy Overview

19. Assumptions and Acronyms Used

20. Research Methodology